发明名称 FcgammaRIIb-specific Fc region variant
摘要 (Problem) To provide: a Fc region variant which has such a property that the binding activity to FcγRIIb is increased and/or the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R) is increased when compared with a polypeptide that contains a Fc region having no amino acid modification introduced thereinto; a polypeptide containing the Fc region variant; a pharmaceutical composition containing the polypeptide; a therapeutic or prophylactic agent for immune inflammatory diseases, which comprises the pharmaceutical composition; methods for producing the aforementioned products; and a method for increasing the binding activity to FcγRIIb and also increasing the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R). (Solution) It is found that a polypeptide which contains an antibody Fc region variant comprising an amino acid sequence containing the combination of the amino acid modification at position-238 as numbered in accordance with the EU numbering method and the amino acid modification at another specific position has such a property that the binding activity to FcγRIIb is increased and/or the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R) is increased.
申请公布号 AU2013306700(A1) 申请公布日期 2015.02.12
申请号 AU20130306700 申请日期 2013.08.23
申请人 CHUGAI SEIYAKU KABUSHIKI KAISHA 发明人 KATADA, HITOSHI;KADONO, SHOJIRO;MIMOTO, FUTA;IGAWA, TOMOYUKI
分类号 C12N15/09;A61K39/395;A61K47/42;C07K16/28;C07K19/00 主分类号 C12N15/09
代理机构 代理人
主权项
地址